Mosunetuzumab plus polatuzumab vedotin achieved an 88.1% objective response rate in heavily pretreated relapsed/refractory mantle cell lymphoma patients, including high-risk groups.
- Open access
- 5 cites
Lymphoma Diagnosis and Treatment
Moving in Blood.
- Moved this week
- 1
Rebuilt
Moved this week
Latest in Lymphoma Diagnosis and Treatment
Newest first · last 60 days
Single-cell RNA sequencing reveals oncogenic transcriptional programs and immune escape mechanisms in over 2 million cells from CTCL patients, highlighting therapeutic vulnerabilities.
DOT1L regulates ncPRC1 complexes and H2AK119ub1 to sustain germinal center B cell identity in diffuse large B cell lymphoma, with 20 key gene targets identified.
Harmonizing trial design and biomarker integration is essential to improve personalized treatment for large B-cell lymphoma patients.
Venetoclax combined with pediatric-inspired chemotherapy achieves a 91% remission rate and improves survival in adolescents and adults with newly diagnosed Ph-negative ALL.
- Open access
- 1 cites
Five conserved malignant B cell archetypes, including a quiescent memory B cell-like type, predict clinical outcomes in large B cell lymphomas, with Archetype 4 linked to poor survival.
- Open access
IL-16-driven signaling mediates resistance to BTK inhibitors and R-CHOP in B-cell lymphomas, with IL-16 upregulation observed in resistant cases.
- Open access
- 6 cites
IGH::FENDRR and KRAS mutations define a novel B-ALL subtype with 85% poor chemotherapy response.
- Open access
Deletion of cFLIP in B cells prevents diffuse large B-cell lymphoma development in mice, highlighting its essential role in lymphoma pathogenesis.
- Open access
- 1 cites
Elevated SYTL4 expression is linked to poorer prognosis and may serve as a diagnostic, prognostic, and therapeutic biomarker in DLBCL, with a hazard ratio of 25.541.
- Open access
EBV transcriptional regulators extensively alter human gene expression, with over 100,000 binding events affecting nearly a quarter of human genes.
- Open access
- 3 cites
Mosunetuzumab plus polatuzumab vedotin achieved an 88.1% objective response rate in heavily pretreated relapsed/refractory mantle cell lymphoma patients, including high-risk groups.
- Open access
- 5 cites
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4